Cambridge, Massachusetts-based Magenta Therapeutics, a biotechnology company focused on improving and expanding the use of curative stem cell transplantation for more patients, has closed $50 million in Series B funding. GV led the round with participation from other investors that included Atlas Venture, Third Rock Ventures, Partners Innovation Fund, Access Industries and Casdin Capital.